Skip to main content

Table 1 Clinical and pathological patient characteristics

From: Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study

  Patients (N) EGFR mut + (N) EGFR mut + (%)
Total group 297 32 11
Gender    
Female 113 26 23
Male 184 6 3
Age    
<60 80 7 9
60-70 99 10 10
>70 118 15 13
Smoking    
Never 40 16 40
Former 109 8 7
Current 99 7 7
Missing 49 1 -
Specimen    
Cytology 84 8 10
Biopsy 213 24 11
Tumour histology    
Adeno 274 31 11
NSCLC-NOS 9 1 11
Squamous 14 0 0
EGFR IHC    
Positive 254 29 12
Negative 9 0 0
Missing 34 3 -
TTF-1 IHC    
Positive 171 29 17
Negative 45 1 2
Missing 81 2 -
  1. EGFR mut+: presence of activating EGFR mutation; N: number; NSCLC-NOS: non-small cell lung cancer not otherwise specified; IHC: immunohistochemistry; TTF-1: thyroid transcription factor 1.